Anxiety disorders are currently one of the most common diseases in industrialized countries, showing a continuous upward trend. Classic therapy was based on GABA receptor modulation. However, numerous side effects associated with the impact on this neurotransmission led to the search for new drugs. The involvement of other messengers like serotonin, dopamine and noradrenaline in the pathophysiology of anxiety disorders, resulted in the introduction of SSRI, SNRI, TLPD and azapirones. However, these drugs are not fully effective, have many limitations and side effects, hence the problem of finding new solutions in anxiety therapy is still valid. One of new theories indicates the role of the endocannabinoid system in the diagnosis and treatment of anxiety. It is well known, that the main endogenous cannabinoids – anandamide (AEA) and 2-arachidonoglicerol (2-AG) – are metabolized by the enzymes from the serine hydrolase group: fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). This review presents a new compounds form the froup of endocannabinoid degradation inhibitors with anxiolytic activity
Support the magazine and subscribe to the content
This is premium stuff. Subscribe to read the entire article.